Oncolytics Biotech (NasdaqCM:ONCY) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Oncolytics Biotech to reach your target.
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| ONCY Price (Oncolytics Biotech stock price per share) |
$0.39 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Drug Manufacturers - General stocks | |
| Cash Yield | -25.02% | |
| Free Cash Flow Jitter | 29% |
No open-market insider buys or sells are recorded in the six months to 2026-11-20.
The six months before that had 14 buys and 0 sales.
Open-market buys and sells reported by Oncolytics Biotech's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-12 | Kelly Jared (Chief Executive Officer) | Buy | 5,050 | $0.96 |
| 2026-03-11 | Parsons James T. | Buy | 10,000 | $1.03 |
| 2026-02-12 | Look Kirk (Chief Financial Officer) | Buy | 12,000 | $0.84 |
| 2026-02-12 | Pisano Wayne | Buy | 30,000 | $0.84 |
| 2026-02-12 | Heineman Thomas Charles (Chief Medical Officer) | Buy | 12,132 | $0.83 |
| 2026-02-12 | Brown Deborah Margaret | Buy | 25,000 | $0.85 |
| 2026-02-12 | Kelly Jared (Chief Executive Officer) | Buy | 29,500 | $0.84 |
| 2026-02-12 | Hagerman Allison (VP, Product Development) | Buy | 10,000 | $0.83 |
| 2026-02-12 | Seizinger Bernd R. | Buy | 40,000 | $0.85 |
| 2026-02-12 | Andrews Patricia S | Buy | 35,400 | $0.86 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 8,679,124 shares shorted. With 125,536,642 shares available for purchase and an average trading volume over the past 10 trading days of 1,372,330, it would take at least 6.3 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Free cash flow was negative in every one of the 2 fiscal years we have for Oncolytics Biotech under its current filer.
Free cash flow is uneven from year to year, with a variability measure of 29%.
We do not estimate a fair value for Oncolytics Biotech while its free cash flow growth is not positive, so there is no value comparison here.
Dividends are not in our data for Oncolytics Biotech.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Oncolytics Biotech, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Oncolytics Biotech (ONCY) | 53.2 | - | - | - | - |
| LifeVantage Corporation (LFVN) | 62 | 23.3 | 4.0% | - | 85% above |
| SIGA Technologies (SIGA) | 190 | 265.0 | - | 7.1% | 86% below |
| Collegium Pharmaceutical (COLL) | 783 | 23.1 | - | - | 160% above |
| Amphastar Pharmaceuticals (AMPH) | 1,199 | 12.9 | - | 0.8% | 97% above |
| Innoviva (INVA) | 1,309 | 7.8 | - | - | 12% above |
| Phibro Animal Health Corporation (PAHC) | 1,384 | 13.6 | 1.3% | - | 87% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1129928.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: ONCY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Oncolytics Biotech have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to ONCY: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is Dollar Cost Averaging?
Benjamin Graham, Value Investor
How Do Tariffs Affect the Stock Market?
Precious Metals for Value Investors